Analysis of whether gosatuzumab (Todavi) is a purely targeted drug

Gosatuzumab (Chinese trade name: Trodelvy, English name: Trodelvy, generic name: sacituzumab govitecan) is an antibody-drug conjugate (ADC) that is widely used to treat advanced triple-negative breast cancer (TNBC) and other solid tumors expressing Trop-2. Although it is "targeted" in treatment, strictly speaking, gosatuzumab is not a "pure" targeted drug in the traditional sense, but a compound drug that combines a targeting mechanism with chemotherapy toxins.

The structure of gosatuzumab consists of three parts: a monoclonal antibody against the Trop-2 protein, a linker structure, and the cytotoxic drug SN-38 (the active metabolite of irinotecan). It recognizes and binds to the surface of tumor cells with high expression of Trop-2 through the monoclonal antibody part, thereby accurately delivering the carried SN-38 into the tumor cells, releasing the toxin and then destroying DNA and inducing cell apoptosis. This "directed delivery + killing" mechanism gives it a high degree of targeting, but its ultimate tumor-killing effect still depends on the chemotherapy ingredients.

Compared with classic targeted drugs (such as EGFR and HER2 inhibitors), the mechanism of action of gosatuzumab is more complex and belongs to a mixed model of "half-targeted and half-chemotherapy". It does not block tumor growth by inhibiting signaling pathways like pure targeted drugs, but by identifying tumor-specific antigens to locate and then release toxic substances. Therefore, the side effects are similar to traditional chemotherapy drugs, such as neutropenia, diarrhea, nausea, etc., which require close monitoring.

To sum up, gosatuzumab is not a "pure targeted drug", but an advanced form of antibody- drug conjugate, which has both targeting and chemotherapy lethality. It represents the cutting-edge technology of ADC drugs in the field of tumor treatment, and provides a new treatment option for patients with advanced cancer for whom traditional chemotherapy is ineffective. However, because its toxic and side effects are still obvious, the pros and cons of medication need to be scientifically evaluated based on individual condition, tolerance and doctor's guidance during use.

Reference materials:https://www.drugs.com